Efficacy of lumiracoxib versus diclofenac sodium in pain control following extraction of impacted lower third molar / Eficacia de lumiracoxib frente a diclofenaco de sodio en el control del dolor después de la extracción de un tercer molar inferior impactado

The aim of this paper was to compare the efficacy of two different anti-inflammatory agents, Diclofenac (Deltaflogin®) and Lumiracoxib (Prexige®) in the control of postoperative pain that results from surgical removal of impacted lower third molars. Twenty adult patients from the Oral and Maxillofacial Surgery Division of the Araraquara Dentistry School, UNESP who presented bilateral impacted lower third molars were included in the study. Removal of the impacted teeth was performed in each side in different operative moments in a split mouth design for the study. The anti-inflammatory drugs evaluated were randomly administered on the first and second surgical procedures. The pain level was recorded using an analogical visual scale at 6, 24, 48 and 72 hours after surgical intervention. Both lumiracoxib 400 mg and diclofenac 100 mg are efficient for acute pain control after surgical removal of impacted lower third molars. However, lumiracoxib offered better pain control.

El objetivo de este trabajo fue comparar la eficacia de dos agentes antiinflamatorios distintos, Diclofenaco (Deltaflogin®) y Lumiracoxib (Prexige®) en el control del dolor postoperatorio resultante de la extracción quirúrgica de terceros molares inferiores impactados. Fueron incluídos, veinte pacientes adultos de la División de Cirugía Oral y Maxilofacial de la Escuela de Odontología de Araraquara, UNESP que presentaron terceros molares inferiores impactados. La extracción de los dientes impactados se realizó en distintos tiempos operatorios a cada lado en un diseño de estudio de boca dividida. Los antinflamatorios evaluados fueron administrados de forma aleatoria en el primer y segundo procedimento quirúrgico. El nivel de dolor se registró utilizando una escala visual análoga a las 6, 24, 48 y 72 horas después de la intervención. Ambos; lumiracoxib 400 mg y diclofenaco 100 mg son eficientes para el control del dolor agudo, después de la extracción quirúrgica de terceros molares inferiores impactados. Sin embargo, lumiracoxib ofreció mejor control del dolor.

Isolation and preliminary evaluation of Mulva Neglecta mucilage: a novel tablet binder

ABSTRACT The aim of this study was to evaluate binding potential of Mulva neglecta mucilage (MNM) with subsequent comparison to PVP K30. Eight batches of Diclofenac sodium tablets were prepared by wet granulation technique keeping different concentrations (4, 6, 8 & 10% w/w) of Mulva neglecta mucilage (extracted from leaves of Mulva neglecta) and PVP K30 as standard binder. The granules of formulated batches showed bulk density (g/mL) 0.49 ± 0.00 to 0.57 ± 0.00, tapped density (g/mL) 0.59 ± 0.01 to 0.70 ± 0.01, Carr's index 09.27 ± 0.95 to 19.65 ± 0.59, Hausner's ratio 1.12 ± 0.00 to 1.24 ± 0.01 and angle of repose 30.37 ± 2.90 °C to 36.86 ± 0.94 °C. Tablets were compressed to hardness 7.50 to 7.95 kg/cm2. The tablets showed 0.39 ± 0.02 to 0.39 ± 0.01% friability and 7:20 to 14:00 min disintegration time. Granules and post-compression evaluation revealed that parameters assessed were all found to be within the pharmacopoeial limits. The results (hardness, disintegration and dissolution) proved that Mulva neglecta mucilage has better binding capacity for preparation of uncoated tablet dosage form as compared to PVP K30. Among all the formulations, MN-1 to MN-4 showed slow release as compared to PV-1 to PV-4 and thereby Mulva neglecta mucilage exhibited satisfactory drug release phenomenon tablets of diclofenac sodium.

RESUMO O objetivo deste estudo foi avaliar o potencial de ligação de mucilagem de Mulva neglecta (MNM), com posterior comparação ao PVP K30. Oito lotes de comprimidos de diclofenaco de sódio foram preparados pela técnica de granulação úmida, mantendo diferentes concentrações (4, 6, 8 e 10% w/w) de mucilagem de Mulva neglecta (extraída de folhas de Mulva neglecta) e PVP K30 como ligante padrão. Os grânulos de lotes formulados mostraram densidade aparente (g/mL) 0.49 ± 0.00-0.57 ± 0.00, densidade compactada (g/mL) 0.59 ± 0.01-0.70 ± 0.01, índice de Carr 09.27 ± 0.95-19.65 ± 0.59, a relação de Hausner 1.12 ± 0.00-1.24 ± 0.01 e ângulo de repouso 30.37 ± 2.90 °C a 36.86 ± 0.94 °C. Os comprimidos foram prensados à dureza de 7.50-7.95 kg/cm2. Os comprimidos apresentaram 0.39 ± 0.02-0.39 ± 0.01% friabilidade e 7:20-14:00 min de tempo de desintegração. A avaliação de grânulos e pós-compressão revelou que todos os parâmetros estavam dentro dos limites da farmacopeia. Os resultados (dureza, desintegração e dissolução) provaram que a mucilagem de Mulva neglecta tem maior capacidade de ligação na preparação da forma de dosagem de comprimido não revestido em relação à PVP K30. Entre todas as formulações, MN-1 e MN-4 mostraram liberação lenta em comparação com PV-1 e PV-4 e, assim, a mucilagem de Mulva neglecta exibiu liberação do fármaco satisfatória para os comprimidos de diclofenaco de sódio.

Steroidal and non-steroidal cyclooxygenase-2 inhibitor anti-inflammatory drugs as pre-emptive medication in patients undergoing periodontal surgery

The aim of the present study was to compare the pre-emptive use of a cyclooxygenase-2 (COX-2) inhibitor with a well established steroidal anti-inflammatory drug for pain and edema relief following periodontal surgery for crown lengthening. Thirty patients requiring periodontal surgery were randomly assigned to receive one of the following medications: selective COX-2 inhibitor or steroidal anti-inflammatory drug, 60 min before the surgical procedure. To examine patient anxiety, a Corah's dental anxiety scale was applied before surgery. Using a visual analog scale, the extent of pain/discomfort during the trans-operative period and immediately after the surgery was measured. Additionally, intensity of pain/discomfort and edema were examined 4, 8, 12 and 24 h postoperatively. With regard to anxiety, no statistical differences between the groups were observed (p>0.05). With respect to the extent of pain/discomfort during the trans-operative, immediate and late postoperative period, data demonstrated no significant differences (p>0.05) between the COX-2 inhibitor and steroidal groups. With regard to edema, intragroup analysis did not reveal any statistically significant difference (p>0.05) during the 24 h following surgery in either group. In conclusion, both anti-inflammatory drugs presented a similar potential for pain and edema relief following periodontal surgery.

O objetivo do presente estudo foi comparar a utilização pré-emptiva de medicamento inibidor da COX-2 (cicloxigenase-2) com uma droga antinflamatória esteroidal amplamente utilizada, para o controle da dor e edema após cirurgia periodontal para aumento de coroa. Trinta pacientes que necessitavam de cirurgia periodontal foram aleatoriamente designados a receber uma das seguintes medicações: inibidor seletivo da COX-2 ou a droga antinflamatória esteroidal, 60 min antes do procedimento cirúrgico. Para avaliar a ansiedade do paciente, a escala de ansiedade ao tratamento dental de Corah foi aplicada antes da cirurgia. Com a utilização de escala analógica visual a extensão de dor/desconforto durante o período trans-cirúrgico e imediatamente após a cirurgia foi mensurada. Adicionalmente, a intensidade de dor/desconforto e edema foram avaliados no periodo pós-operatório tardio 4, 8, 12 e 24 h após o procedimento cirúrgico. Com relação à ansiedade, não foi observada diferença estatística entre os grupos (p>0,05). Com relação à extensão de dor/desconforto durante os períodos trans-cirúrgico e pós operatório imediato e tardio, os dados não demonstraram diferenças entre o grupo que recebeu o inibidor seletivo da COX-2 e o aintinflamatório esteroidal (p>0,05). A avaliação do edema, intragrupo, não revelou diferença estatística durante as primeiras 24 h em nenhum dos grupos estudados (p>0,05). Em conclusão, ambas as drogas antiinflamatórias utilizadas apresentaram um potencial similar no controle da dor e edema após cirurgia periodontal.

Effect of aceclofenac on pharmacokinetic of phenytoin

Aceclofenac is presently most commonly prescribed analgesic for chronic pain and inflammatory conditions. In clinical practice, phenytoin and aceclofenac are used in a chronic condition of generalized seizure with concomitant chronic pain. Hence there are chances of drug-drug interaction because modulations of isoenzymes involved in metabolism of phenytoin and aceclofenac are CYP2C9/10 and CYP2C19. It is important to maintain the therapeutic level of phenytoin in plasma for effective control of seizure. So, the aim of the study was to determine the effect of aceclofenac on the pharmacokinetics of phenytoin in rabbits. In a parallel design study, phenytoin 30 mg/kg/day per oral was given daily for seven days. On day 7, blood samples were taken at various time intervals between 0-24 hours. In aceclofenac group, phenytoin was administered for seven days as above. On day 8, aceclofenac 14 mg/kg alongwith phenytoin 30 mg/kg/day was administered and blood samples drawn as above. Plasma phenytoin levels were assayed by HPLC and pharmacokinetic parameters were calculated. In aceclofenac group, there was decrease in t[1/2]el than phenytoin group significant changes were observed in the pharmacokinetic parameters in aceclofenac treated group. These results suggest that aceclofenac alter the pharmacokinetics of phenytoin. Confirmation of these results in human studies will warrant changes in phenytoin dose or frequency when aceclofenac is co-administered with it

A prospective observational study to assess quality of life and prescription pattern in osteoarthritis patients at tertiary health centre in Mumbai.

Background: Osteoarthritis (OA) is a major cause of disability and is focused in "Bone and Joint Decade" declared by WHO which substantially affect different dimensions of quality of life. The aim of present study was to find the disease pattern in OA patients, monitoring prescription pattern to assess prognosis of osteoarthritis by WOMAC index. Materials and Methods: An observational study on prospective data collected for the evaluation of Quality of Life (QOL) in OA was conducted at tertiary health care centre in Mumbai. Patients with a diagnosis of OA were enrolled. The patient's history and clinical examination was based on classification criteria of the American College of Rheumatology; drugs prescribed were noted on case record form. Same procedure was carried out for the first and second follow-ups at 6 th and 12 th weeks respectively. Results: The patients belong to primary OA (84%) as compared to secondary OA (16%). Females (70.56% and 10%) were affected more commonly than males (13.44% and 6%). Knee Joint was worst affected in 76%, followed by hip joint in 16% and shoulder, ankle, wrist, elbow joint each having 2% (n=1) involvement. NSAIDs continued to dominate prescriptions given to 84% of patients followed by antiarthritic drugs and calcium supplements in 54% cases. The WOMAC score was higher in most of patients. After medication hydroxy chloroquine sulfate has shown maximum reduction in average WOMAC sore followed by paracetamol, indomethacin and diclofenac sodium. Conclusion: Osteoarthritis has a significant impact on quality of life, only partly ameliorated by anti-arthritic drugs, as assessed by the WOMAC scale in this study population. Further, a study with larger sample size is needed to further support our findings.

Lumiracoxib for acute postoperative dental pain: a systematic review of randomized clinical trials / Lumiracoxibe para dor dental aguda e pós-operatória: uma revisão sistemática de ensaios clínicos randomizados

CONTEXT AND OBJECTIVE: Lumiracoxib is an anti-inflammatory drug that has been used to treat acute dental pain, mainly in postsurgical settings, in which the greatest levels of pain and discomfort are experienced during the first 24 hours. This study aimed to assess the efficacy and safety of lumiracoxib for treating acute postsurgical dental pain. DESIGN AND SETTING: Systematic review developed at the Brazilian Cochrane Centre, Universidade Federal de São Paulo. METHODS: An electronic search was conducted in the PubMed, Cochrane Library, Lilacs (Literatura Latino-Americana e do Caribe em Ciências da Saúde), SciELO (Scientific Electronic Library Online) and Embase databases. A manual search was also performed. Only randomized controlled trials were included, and these were selected and assessed by two researchers with regard to the risk of bias. RESULTS: Three clinical trials with 921 participants were included. Lumiracoxib 400 mg produced onset of analgesia in a shorter time than shown by lumiracoxib 100 mg, celecoxib 200 mg and ibuprofen 400 mg. There was no difference between lumiracoxib 400 mg and rofecoxib 50 mg. In two studies, the mean time taken to attain onset of analgesia for the placebo was not estimated because the number of participants who reached onset was too small. CONCLUSION: There is evidence with a moderate risk of bias that recommends the use of lumiracoxib for acute postoperative dental pain. However, the adverse effects are not completely known. Given that lumiracoxib is currently available in only three countries, further studies are likely to be rare and discouraged.

CONTEXTO E OBJETIVO: O lumiracoxibe é um anti-inflamatório que tem sido utilizado no tratamento de dor dental aguda, principalmente no cenário pós-cirúrgico, no qual níveis mais elevados de dor e desconforto são sentidos durante as primeiras 24 horas. Este estudo teve por objetivo avaliar a eficácia e a segurança do lumiracoxibe no tratamento da dor dental aguda e pós-operatória. TIPO DE ESTUDO E LOCAL: Revisão sistemática desenvolvida no Centro Cochrane do Brasil, Universidade Federal de São Paulo. MÉTODOS: Foi realizada busca eletrônica nas bases de dados PubMed, Cochrane Library, Lilacs (Literatura Latino-Americana e do Caribe em Ciências da Saúde), SciELO (Scientific Electronic Library Online) e Embase. Também foi realizada busca manual. Apenas ensaios clínicos randomizados foram incluídos e foram selecionados e avaliados por dois pesquisadores quanto ao risco de viés. RESULTADOS: Foram incluídos três ensaios clínicos com 921 participantes. O lumiracoxibe 400 mg mostrou menor tempo de início de analgesia que o lumiracoxibe 100 mg, celecoxibe 200 mg e ibuprofeno de 400 mg. Não houve diferença entre lumiracoxibe 400 mg e rofecoxibe 50 mg. Em dois estudos o tempo médio de início de analgesia para o placebo não foi estimado, pois o número de participantes que a alcançou foi pequeno. CONCLUSÃO: Há evidências, com moderado risco de viés, que recomendam o uso de lumiracoxibe para a dor dental aguda e pós-operatória. No entanto, os efeitos adversos não são completamente conhecidos. Considerando que o lumiracoxibe está disponível em apenas três países, provavelmente a realização de pesquisas futuras será rara e desestimulada.

Aceclofenac delivery by microencapsulation using LBL self-assembly for delayed release

Colonic targeting has gained increasing interest over the past years, not just for the transport of drugs for the treatment of local diseases associated with the colon but also for its potential for transporting peptides and proteins, particularly low molecular weight peptide drugs. Without protection, such peptide drugs are usually digested within the gastric and small intestinal sections. In the present work Layer-By-Layer [LBL] self-assembly was utilized to make Aceclofenac single bilayer microcapsules produced by sequential adsorption of positively charged chitosan and negatively charged Pectin on the external surface of negatively charged Aceclofenac microcrystals. Taguchi approach was applied to determine the best concurrence of composition factors that is concentration of chitosan, pectin, centrifugation speed and incubation time. The microcapsules were characterized for encapsulation efficiency, particle size, zeta potential, scanning electron microscopy and in-vitro release kinetics. Surface electric potential of Aceclofenac microcrystals was found to be negative with zeta potential -1.39 mV, in acetate buffer of pH 4. The primary and the secondary deposit layer of chitosan and pectin was found to have a positive and negative charge with zeta potential of +5.57 mV and -22.8 mV respectively. The sequential changing of surface zeta potential after each deposition is a satisfactory indication of the LBL self-assembly of the oppositely charged polyelectrolytes. The average size and encapsulation efficiency of the optimized single bilayer microcapsules [F5] was found to be 20microm and 63.83%, respectively. The ex-vivo percentage cumulative drug release of [F5] in Phosphate buffer pH 6.8 containing 2-4% w/v colonic fecal matter of male albino rat was found to be 98.40%. The optimized batch of microcapsules showed first order release kinetics [R[2]= 0.950] in presence of colonic fecal matter

Synthesis and pharmacological evaluation of tyrosine and glycine prodrugs of aceclofenac

The gastrointestinal toxicity associated with aceclofenac [AC] can be reduced by synthesis of its prodrugs. It involves condensing the carboxylic acid group of AC with methyl esters of amino acids like tyrosine and glycine to give tyrosine conjugated aceclofenac [3a] and glycine conjugated aceclofenac [3b], respectively. Physicochemical characterization of the prodrugs by various analytical and spectral methods was carried out. In vitro hydrolysis in simulated gastric fluid [SGF], simulated intestinal fluid [SIF] and human plasma showed an encouraging hydrolysis rate in SIF and human plasma than in SGF. This indicated that the prodrugs do not break in stomach but release aceclofenac in SIF and human plasma. The pharmacological evaluations showed a comparable increase in anti-inflammatory activity and marked reduction of ulcer index for the prodrugs. Normal histological findings revealed that the prodrugs are not producing any ulceration in the gastric region. The prodrugs thus possess better pharmacological response than the parent drug

Avaliação do efeito analgésico preemptivo do lumiracoxibe comparado com placebo nas primeiras 24 horas de pós-operatório / Evaluation of the analgesic effects of the lumiracoxib compared with placebo in the 24 first postoperative hours

OBJETIVO: Testar o lumiracoxibe, utilizado preemptivamente contra um placebo, e analisar o consumo de analgésicos (dipirona e tramadol) nas primeiras 24h do pós-operatório. MÉTODOS: Sessenta pacientes submetidas à mamoplastia de aumento, sob anestesia peridural, foram selecionadas e divididas de forma randomizada em dois grupos - GI e GII. Sessenta minutos antes da operação, por via oral, as 30 pacientes do GI receberam um comprimido de lumiracoxibe 400mg, e as 30 do GII um comprimido de placebo. A dor pós-operatória foi avaliada através da escala analógica visual, graduada de 0 (sem dor) a 10 (dor de maior intensidade), sendo aplicada sempre que houvesse referência de dor. Para escores obtidos iguais ou menores que 4, a paciente recebia 15mg/kg de dipirona, até máximo de um grama, via venosa. Para escores de 5, 6 ou 7, recebia 50mg de tramadol por via venosa. Escores de 8 ou mais eram tratados com 0,5mg/kg de meperidina endovenosa. RESULTADOS: Os escores obtidos no GI foram significativamente menores que os do GII dentro das primeiras 24 horas, resultando em consumo 20 por cento menor de dipirona e 56 por cento menor de tramadol. Da mesma forma, observou-se que o tempo para solicitação de analgésicos pela primeira vez no pós-operatório foi de 191 minutos maior no GI. CONCLUSÃO: O emprego do lumiracoxibe preemptivamente mostrou-se efetivo no combate à dor pós-operatória, reduzindo consideravelmente o consumo global de analgésicos nesse período e aumentando o tempo de solicitação de analgésico pela primeira vez.

OBJECTIVES: To test lumiracoxib used preemptively against a placebo,and to analyse the analgesic administration (dipirona and tramadol) in the 24 first postoperative hours. METHODS: Sixty patients undergone to a breast aumentation, under epidural anesthesia, were selected and put randomly in two groups - GI and GII. Sixty minutes before the surgery, it was administered orally, one pill of lumiracoxib 400mg to the 30 GI patients and one pill of placebo to the 30 GII patients. The postoperative pain was evaluated through the visual analogic scale, ranged from 0 (painless) to 10 (most intensive pain), being applied to the patient whenever having pain. For the same scores or under 4, it was administered intravenously 15mg/kg of dipirona up to a maximum of 1g. For scores of 5, 6 or 7, the patient had intravenously 50mg of tramadol.Scores 8 or more were treated intravenously with 0,5 mg/kg of meperidine. RESULTS: The scores in GI were significantly lower than the ones obtained in GII within the first 24 hours, with the need of 20 percent less dipirona and 56 percent of tramadol in this period of time. In the same way, it was observed that analgesic solicitation for the first time had a delay of 191 minutes in GI in comparison to GII. CONCLUSION: The use of lumiracoxib preemptively, was effective in the treatment of postoperative pain, reducing considerably the consume of analgesics, and enlarging the time for the first medication.

PARFLEX--a very useful drug for management of surgical pain.

The aim was to assess and document the efficacy and tolerability of parflex (FDC of aceclofenac with paracetamol and serratiopeptidase) in management of pain and inflammation in adult patients undergoing surgical procedures (or operations). The design was open, prospective, non-comparative and multi-dose study of patients undergoing surgical procedures at a leading, tertiary-care, teaching hospital (setting) in Lucknow, the name being, King George's Medical College, Lucknow 226003. The patients were 50 adult patients of either sex undergoing surgery. They were given 1 tablet twice daily, taken after meals. Treatment duration was for a total of up to 7 days (intervention). Primary efficacy variables were relief from postoperative pain. Secondary efficacy variables were global assessment of efficacy and toleration by patients and treating physicians. Record was made of spontaneously reported adverse events with their nature, intensity and outcome (tolerability). Out of 50 patients, 31% were (ENT), 36% were (Orthopaedic) and 33% were (Gynaecology). They were enroled in this study. The observations made were mean pain score showed significant improvement with study drug - decreasing from 2.66 at baseline to 1.36 after 48 hours, and to 0.8 at the end of study. Composite score for pain, fever and swelling also showed substantial gains visit-on- visit-decreasing from 3.62 at baseline to 2.04 after 48 hours, and to 0.98 at final visit. None of the patients reported any adverse event. Global efficacy assessment was rated as 'excellent or good' by 54% of patients and in 59% of patients by their treating physicians. To conclude, parflex is an effective analgesic, anti-inflammatory drug that has a valuable therapeutic option for controlling pain and inflammation after surgical procedures.

Comparative efficacy of aceclofenac and etoricoxib in post extraction pain control: randomized control trial.

The study is a prospective randomized double blind clinical trial comparing the efficacy of nonselective NSAIDs (Aceclofenac) and highly selective COX-2 inhibitors (Etoricoxib) in post extraction pain control. The primary efficacy was judged by overall assessment of onset and duration of analgesic effect and rate of decrease in pain intensity by a visual analogue scale over a 3-day investigation period. 100 patients were enrolled in the study (50 patients in aceclofenac group and 50 patients in etoricoxib group). Twice-daily dosage of aceclofenac 100 mg and etoricoxib 60 mg were recommended for the double blind study. 64 patients completed the study. Efficacy of pain control over baseline data documented in both the treatment groups were statistically significant (p<0.05). There was no significant difference between the two drugs.

Estudo randomizado do nimesulide, aceclofenaco e diclofenaco no tratamento de afecçöes traumáticas do aparelho locomotor / Randomized study nimesulide, aceclofenac and diclofenac in the treatment of traumatic injuries of the locomotor system

Diante dos novos conceitos resultantes da descoberta da existência de dois subtipos de ciclooxigenase (COX), COX-1 (constitutiva) e COX-2 (indutiva), o objetivo deste estudo foi avaliar a eficácia e tolerabilidade, no tratamento de afecçoes traumáticas do aparelho locomotor, de três antiinflamatórios nao hormonais (AINHs): nimesulide, o primeiro AINH inibidor seletivo da COX-2 disponível, e dois agentes clássicos nao seletivos, diclofenaco e aceclofenaco. Em três visitas clínicas e após sete dias de tratamento em que randomicamente 19 pacientes receberam nimesulide 100mg 2x/dia, 19 receberam aceclofenaco 100mg 2x/dia e 21 receberam diclofenaco 50mg 3x/dia, a eficácia foi avaliada clinicamente segundo a intensidade dos sinais e sintomas e pela avaliaçao global do pesquisador ao final do estudo, e a tolerabilidade pela ocorrência ou nao de eventos adversos bem como pela avaliaçao global ao término do estudo. Quanto à eficácia, o resultado obtido pelo grupo tratado com nimesulide foi significativamente melhor considerando-se os parâmetros dor à movimentaçao, limitaçao de movimentos, sensibilidade local e intensidade da dor. Também quanto à tolerabilidade, tanto o índice de ocorrência de reaçoes adversas como a avaliaçao final global foram significativamente melhores para o grupo nimesulide. Confirmando estudos anteriores, a seletividade de nimesulide sobre a COX-2 contribui para sua eficácia, assim como reflete seu perfil de segurança, ao contrário do aceclofenaco e diclofenaco, que nao têm esse grau de seletividade sobre a COX-2. Portanto, nimesulide pode ser considerado um antiinflamatório e analgésico de primeira escolha no tratamento de afecçoes traumáticas do aparelho locomotor.

Açåo do diclofenaco potássico nos processos inflamatórios de várias etiologias: estudo multicêntrico / Efficacy of diclofenac potassium action in acute inflammation conditions of varying etiologies: multicentric study

Såo relatados os resultados obtidos em um estudo com 328 pacientes que apresentavam processos inflamatórios nåo reumáticos de várias etiologias na área de ginecologia, ortopedia, otorrinolaringologia e pediatria tratados com o diclofenaco potássico durante três a 10 dias. Participaram deste estudo multicêntrico 87 médicos de inúmeros centros do país. Os resultados obtidos permitem inferir que a eficácia clínica do diclofenaco potássico foi considerada excelente a boa em 96,9 por cento e 94,5 por cento dos casos, na opiniåo de médico e paciente respectivamente. O diclofenaco potássico constitui, sem dúvida, um eficaz e seguro agente terapêutico para controlar os processos inflamatórios agudos de varias etiologias

Uso de uma formulaçäo de diclofenaco resinato gotas em pediatria e otorrinolaringologia: ensaio aberto multicêntrico / Diclofenac resinate drops in pediatrics and otorhinolaryngology: an open multicentre study

Ensaio aberto multicêntrico reunindo 1.650 pacientes pediátricos e adultos jovens com infecçöes das vias aéreas superiores, inferiores, vias urinárias, órgäos genitais e traumatismos. Os pacientes se submeteram a um tratamento com diclofenaco resinato gotas orais, na posologia de 0,6 mg/kg de peso corporal, em duas ou três tomadas diárias, para avaliaçäo da eficácia e da tolerabilidade da medicaçäo como terapêutica concomitante nos diferentes grupos de patologias. Verificou-se uma reduçäo acentuada dos sinais e sintomas já no terceiro dia de tratamento e o resultado da avaliaçäo global foi considerada muito eficaz/ eficaz em 94,3 por cento dos casos. O tratamento teve uma duraçäo média de seis dias e os efeitos colaterais estiveram presentes em 4,4 por cento dos pacientes avaliados